Molecular characterisation of cyp51A and cyp51B genes coding for P450 14α-lanosterol demethylases A (CYP51Ap) and B (CYP51Bp) from voriconazole-resistant laboratory isolates of Aspergillus flavus

Suganthini Krishnan-Natesan, Pranatharthi H. Chandrasekar, George J. Alangaden, Elias Kurian Manavathu

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Aspergillus flavus is the second most common Aspergillus spp. causing invasive infections in immunocompromised patients. Extensive prophylactic use of voriconazole (VCZ) in immunocompromised patients may enhance the selection of VCZ-resistant clinical isolates of A. flavus, compromising the effectiveness of this antifungal drug against A. flavus infection. To study triazole resistance, we selected A. flavus isolates in the laboratory showing reduced in vitro susceptibility to VCZ. The cyp51A and cyp51B genes coding for P450 14α-sterol demethylases A (CYP51Ap) and B (CYP51Bp) were characterised to examine possible drug target modification-dependent resistance to VCZ in this fungus. High-molecular-weight DNA was isolated from 10 A. flavus isolates showing in vitro resistance to VCZ (minimum inhibitory concentration (MIC) range 4-32 μg/mL) as well as from the drug-susceptible parent isolate X26728 (MIC = 1 μg/mL). The cyp51A and cyp51B genes were cloned and the nucleotide sequences were determined. A comparison of the deduced amino acid sequences of CYP51Ap from 10 VCZ-resistant isolates with that of the drug-susceptible parent showed no amino acid variation in six of the ten isolates. CYP51Ap from isolates Afl-VCZ6 and Afl-VCZ46 showed a K197N change, CYP51Ap from isolate Afl-VCZ114 showed Y132N and T469S changes, whereas that from isolate Afl-VCZ45 showed K197N, D282E and M288L changes. These results suggest that VCZ-resistant A. flavus isolates can be readily isolated in the laboratory under selection pressure. Multiple mechanisms, including drug target modification, may be responsible for the in vitro resistance of A. flavus to VCZ.

Original languageEnglish (US)
Pages (from-to)519-524
Number of pages6
JournalInternational Journal of Antimicrobial Agents
Volume32
Issue number6
DOIs
StatePublished - Dec 1 2008

Fingerprint

Lanosterol
Aspergillus flavus
Genes
Pharmaceutical Preparations
Immunocompromised Host
Microbial Sensitivity Tests
Sterol 14-Demethylase
Triazoles
Voriconazole
Aspergillus
Infection
Amino Acid Sequence
Fungi
Molecular Weight
Amino Acids
Pressure

Keywords

  • Aspergillus
  • Gene
  • Lanosterol demethylase
  • Mutants
  • Resistance
  • Voriconazole

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases
  • Pharmacology (medical)

Cite this

Molecular characterisation of cyp51A and cyp51B genes coding for P450 14α-lanosterol demethylases A (CYP51Ap) and B (CYP51Bp) from voriconazole-resistant laboratory isolates of Aspergillus flavus. / Krishnan-Natesan, Suganthini; Chandrasekar, Pranatharthi H.; Alangaden, George J.; Manavathu, Elias Kurian.

In: International Journal of Antimicrobial Agents, Vol. 32, No. 6, 01.12.2008, p. 519-524.

Research output: Contribution to journalArticle

@article{450e36b3fcd44a8e8c96c9e443f2d800,
title = "Molecular characterisation of cyp51A and cyp51B genes coding for P450 14α-lanosterol demethylases A (CYP51Ap) and B (CYP51Bp) from voriconazole-resistant laboratory isolates of Aspergillus flavus",
abstract = "Aspergillus flavus is the second most common Aspergillus spp. causing invasive infections in immunocompromised patients. Extensive prophylactic use of voriconazole (VCZ) in immunocompromised patients may enhance the selection of VCZ-resistant clinical isolates of A. flavus, compromising the effectiveness of this antifungal drug against A. flavus infection. To study triazole resistance, we selected A. flavus isolates in the laboratory showing reduced in vitro susceptibility to VCZ. The cyp51A and cyp51B genes coding for P450 14α-sterol demethylases A (CYP51Ap) and B (CYP51Bp) were characterised to examine possible drug target modification-dependent resistance to VCZ in this fungus. High-molecular-weight DNA was isolated from 10 A. flavus isolates showing in vitro resistance to VCZ (minimum inhibitory concentration (MIC) range 4-32 μg/mL) as well as from the drug-susceptible parent isolate X26728 (MIC = 1 μg/mL). The cyp51A and cyp51B genes were cloned and the nucleotide sequences were determined. A comparison of the deduced amino acid sequences of CYP51Ap from 10 VCZ-resistant isolates with that of the drug-susceptible parent showed no amino acid variation in six of the ten isolates. CYP51Ap from isolates Afl-VCZ6 and Afl-VCZ46 showed a K197N change, CYP51Ap from isolate Afl-VCZ114 showed Y132N and T469S changes, whereas that from isolate Afl-VCZ45 showed K197N, D282E and M288L changes. These results suggest that VCZ-resistant A. flavus isolates can be readily isolated in the laboratory under selection pressure. Multiple mechanisms, including drug target modification, may be responsible for the in vitro resistance of A. flavus to VCZ.",
keywords = "Aspergillus, Gene, Lanosterol demethylase, Mutants, Resistance, Voriconazole",
author = "Suganthini Krishnan-Natesan and Chandrasekar, {Pranatharthi H.} and Alangaden, {George J.} and Manavathu, {Elias Kurian}",
year = "2008",
month = "12",
day = "1",
doi = "10.1016/j.ijantimicag.2008.06.018",
language = "English (US)",
volume = "32",
pages = "519--524",
journal = "International Journal of Antimicrobial Agents",
issn = "0924-8579",
publisher = "Elsevier",
number = "6",

}

TY - JOUR

T1 - Molecular characterisation of cyp51A and cyp51B genes coding for P450 14α-lanosterol demethylases A (CYP51Ap) and B (CYP51Bp) from voriconazole-resistant laboratory isolates of Aspergillus flavus

AU - Krishnan-Natesan, Suganthini

AU - Chandrasekar, Pranatharthi H.

AU - Alangaden, George J.

AU - Manavathu, Elias Kurian

PY - 2008/12/1

Y1 - 2008/12/1

N2 - Aspergillus flavus is the second most common Aspergillus spp. causing invasive infections in immunocompromised patients. Extensive prophylactic use of voriconazole (VCZ) in immunocompromised patients may enhance the selection of VCZ-resistant clinical isolates of A. flavus, compromising the effectiveness of this antifungal drug against A. flavus infection. To study triazole resistance, we selected A. flavus isolates in the laboratory showing reduced in vitro susceptibility to VCZ. The cyp51A and cyp51B genes coding for P450 14α-sterol demethylases A (CYP51Ap) and B (CYP51Bp) were characterised to examine possible drug target modification-dependent resistance to VCZ in this fungus. High-molecular-weight DNA was isolated from 10 A. flavus isolates showing in vitro resistance to VCZ (minimum inhibitory concentration (MIC) range 4-32 μg/mL) as well as from the drug-susceptible parent isolate X26728 (MIC = 1 μg/mL). The cyp51A and cyp51B genes were cloned and the nucleotide sequences were determined. A comparison of the deduced amino acid sequences of CYP51Ap from 10 VCZ-resistant isolates with that of the drug-susceptible parent showed no amino acid variation in six of the ten isolates. CYP51Ap from isolates Afl-VCZ6 and Afl-VCZ46 showed a K197N change, CYP51Ap from isolate Afl-VCZ114 showed Y132N and T469S changes, whereas that from isolate Afl-VCZ45 showed K197N, D282E and M288L changes. These results suggest that VCZ-resistant A. flavus isolates can be readily isolated in the laboratory under selection pressure. Multiple mechanisms, including drug target modification, may be responsible for the in vitro resistance of A. flavus to VCZ.

AB - Aspergillus flavus is the second most common Aspergillus spp. causing invasive infections in immunocompromised patients. Extensive prophylactic use of voriconazole (VCZ) in immunocompromised patients may enhance the selection of VCZ-resistant clinical isolates of A. flavus, compromising the effectiveness of this antifungal drug against A. flavus infection. To study triazole resistance, we selected A. flavus isolates in the laboratory showing reduced in vitro susceptibility to VCZ. The cyp51A and cyp51B genes coding for P450 14α-sterol demethylases A (CYP51Ap) and B (CYP51Bp) were characterised to examine possible drug target modification-dependent resistance to VCZ in this fungus. High-molecular-weight DNA was isolated from 10 A. flavus isolates showing in vitro resistance to VCZ (minimum inhibitory concentration (MIC) range 4-32 μg/mL) as well as from the drug-susceptible parent isolate X26728 (MIC = 1 μg/mL). The cyp51A and cyp51B genes were cloned and the nucleotide sequences were determined. A comparison of the deduced amino acid sequences of CYP51Ap from 10 VCZ-resistant isolates with that of the drug-susceptible parent showed no amino acid variation in six of the ten isolates. CYP51Ap from isolates Afl-VCZ6 and Afl-VCZ46 showed a K197N change, CYP51Ap from isolate Afl-VCZ114 showed Y132N and T469S changes, whereas that from isolate Afl-VCZ45 showed K197N, D282E and M288L changes. These results suggest that VCZ-resistant A. flavus isolates can be readily isolated in the laboratory under selection pressure. Multiple mechanisms, including drug target modification, may be responsible for the in vitro resistance of A. flavus to VCZ.

KW - Aspergillus

KW - Gene

KW - Lanosterol demethylase

KW - Mutants

KW - Resistance

KW - Voriconazole

UR - http://www.scopus.com/inward/record.url?scp=55249114346&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55249114346&partnerID=8YFLogxK

U2 - 10.1016/j.ijantimicag.2008.06.018

DO - 10.1016/j.ijantimicag.2008.06.018

M3 - Article

C2 - 18775650

AN - SCOPUS:55249114346

VL - 32

SP - 519

EP - 524

JO - International Journal of Antimicrobial Agents

JF - International Journal of Antimicrobial Agents

SN - 0924-8579

IS - 6

ER -